Search

Search Results

• THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

  Elihu Estey

  e2013050

  2013-07-12

  https://doi.org/10.4084/mjhid.2013.050

  2290

  PDF: 821

  HTML: 1651

• Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA

  Michele Puppi, Ilaria Sacchetti, Katia Mancuso, Paola Tacchetti, Lucia Pantani, ilaria Rizzello, Miriam Iezza, Marco Talarico, Enrica Manzato, Simone Masci, Roberta Restuccia, Simona Barbato, Silvia Armuzzi, Barbara Taurisano, Ilaria Vigliotta, Elena Zamagni

  e2025045

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.045

  1850

  PDF: 1395

  HTML: 668

• EVOLVİNG PARADİGMS İN THE MANAGEMENT OF PRİMARY IMMUNE THROMBOCYTOPENİA İN ADULTS: FROM CORTİCOSTEROİDS TO TARGETED BİOLOGİC THERAPİES

  Massimo Martino, Laura Giordano, Maria Bruna Greve, Violetta Marafioti, Caterina Alati

  e2026067

  2026-09-01

  https://doi.org/10.4084/MJHID.2026.067

  286

  PDF: 292

  Html: 67

• Guest Editor: Pellegrino Musto AN UPDATE OF THE APPROPRIATE SEQUENCING FOR SALVAGE THERAPIES IN MULTIPLE MYELOMA

  Gregorio Barila', Francesca Rezzonico, Laura Pavan, Alessandro Corso, Renato Zambello

  e2025043

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.043

  1280

  PDF: 1030

  HTML: 514

• PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA

  Annarosa Cuccaro, Francesca Bartolomei, Elisa Cupelli, Stefan Hohaus

  e2014053

  2014-07-04

  https://doi.org/10.4084/mjhid.2014.053

  3527

  PDF: 2095

  HTML: 7584

• THE DARK SIDE OF THE COVID-19 TREATMENTS ON MYCOBACTERIUM TUBERCULOSIS INFECTION

  Flavio De Maio, Delia Mercedes Bianco, Giovanni Delogu

  e2022021

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.021

  1440

  PDF: 840

  HTML: 333

• OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT

  Ulrike Bacher, Stefanie von Matt, Yara Banz, Behrouz Mansouri, Urban Novak, Thomas Pabst

  e2023025

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.025

  1612

  HTML: 414

  PDF: 1024

  Suppl. Files: 522

• Guest Edtor: Pellegrino Musto NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES

  Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani

  e2025027

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.027

  1561

  PDF: 1338

  HTML: 697

• CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA CAR-T; Large B Cell Lymphoma; Salvage Therapy,

  Ugo Testa, Giuseppe Leone, Elvira Pelosi, Dr. Germana Castelli, Prof. Hohaus

  e2023066

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.066

  3958

  PDF: 1587

  HTML: 359

• MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA

  Alessandro Granito, Luigi Bolondi

  e2009021

  https://doi.org/10.4084/mjhid.2009.021

  784

  PDF: 505

  HTML: 6290

• PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?

  Kalliopi Zachou, Pinelopi Arvaniti, Nikolaos K. Gatselis, Kalliopi Azariadis, Georgia Papadamou, Eirini Rigopoulou, George N. Dalekos

  e2017003

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.003

  3039

  PDF: 1042

  HTML: 2124

  Cover letter: 225

• UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)

  José Luis Piñana, Estela Giménez, Lourdes Vázquez, María Ángeles Marcos, Manuel Guerreiro, Rafael Duarte, Ariadna Pérez, Carlos de Miguel, Ildefonso Espigado, Marta González-Vicent, María Suarez-Lledó, Irene García-Cadenas, Rodrigo Martino, Angel Cedillo, Monserrat Rovira, Rafael de la Cámara, David Navarro, Carlos Solano

  e2024065

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.065

  4648

  Suppl. Files: 1266

  PDF: 1164

  Html: 320

• GREEK CONSENSUS ON CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATMENT

  Sotirios Sachanas, Theodoros Vassilakopoulos, Maria Angelopoulou, sotirios Papageorgiou, Emmanouil Spanoudakis, Maria Bouzani, Maria Dimou, Panagiotis Panagiotidis

  e2025014

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.014

  1559

  HTML: 268

  PDF: 926

• OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES

  Jon Salmanton-Garcia, Francesco Marchesi, Oliver A. Cornely, Jannik Stemler, Pierantonio Menna

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.022

  1803

  PDF: 2037

  Suppl. Files: 288

  HTML: 122

• THE GROWING ROLE OF THE BH3 MIMETIC DRUG VENETOCLAX IN THE THERAPY OF ACUTE MYELOID LEUKEMIA

  Elvira Pelosi, Dr. Germana Castelli, Ugo Testa

  e2022080

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.080

  1708

  PDF: 1274

  HTML: 638

• COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.

  Monia Marchetti , Robert Peter Gale, Giovanni Barosi

  Page e2021034

  2021-04-29

  https://doi.org/10.4084/MJHID.2021.034

  1614

  PDF: 604

  HTML: 263

• Guest Editor: Pellegrino Musto HOW FIRST LINE THERAPY IS CHANGING IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

  Yasmine Houbaida, Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda

  e2025026

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.026

  2120

  PDF: 1767

  HTML: 469

• Internal Medicine Ward with Hematological Skills for the Treatment of Complications Suffered by Hematological Patients on Therapy: Experience of Villa Betania Hospital inRome

  alessandro andriani, Laura Marchetti, Fabio Rossi, Silvia Raja, Maria Antonietta Perretti, Umberto Recine

  e2024030

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.030

  713

  PDF: 1093

  HTML: 114

• THE TREATMENT OF ADVANCED-STAGE MYCOSIS FUNGOIDES AND SEZARY SYNDROME: A HEMATOLOGIST'S POINT OF VIEW.

  Antonio Giordano, Livio Pagano

  e2022029

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.029

  2609

  PDF: 1116

  HTML: 412

• DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES

  Prof. Giuseppe Leone, Emiliano Fabiani, Maria Teresa Voso

  e2022030

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.030

  1726

  HTML: 708

  PDF: 923

• SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs

  Massimo Breccia, Giuliana Alimena

  e2014003

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.003

  3403

  PDF: 1304

  HTML: 3554

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 2- FOCUS ON THERAPY

  Michele Bibas, Shayna Sarosiek , Jorge Castillo

  e2025015

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.015

  2785

  PDF: 2160

  HTML: 900

• INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  AnnaMaria Nosari

  e2012070

  2012-11-05

  https://doi.org/10.4084/mjhid.2012.070

  3611

  PDF: 1470

  HTML: 2735

• PROGNOSIS AND THERAPY WHEN ACUTE PROMYELOCYTIC LEUKEMIA AND OTHER “GOOD RISK” ACUTE MYELOID LEUKEMIAS OCCUR AS A THERAPY-RELATED MYELOID NEOPLASM

  Richard A. Larson, Michelle Le Beau

  e2011032

  2011-07-08

  https://doi.org/10.4084/mjhid.2011.032

  3077

  PDF: 1016

  HTML: 1894

• THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone

  George J Kontoghiorghes, Marios Kleanthous, Christina N. Kontoghiorghe

  e2020011

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.011

  2716

  PDF: 1678

  HTML: 730

• Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

  Daniele Derudas

  e2025025

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.025

  1738

  PDF: 1462

  HTML: 191

• NEW THERAPEUTIC OPTIONS FOR THE TREATMENT OF SICKLE CELL DISEASE Guest Editor: Raffaella Origa

  Alessandro Matte, Filippo Mazzi, Enrica Federti, Oliviero Olivieri, Lucia De Franceschi

  e2019002

  2019-01-01

  https://doi.org/10.4084/mjhid.2019.002

  7182

  PDF: 3814

  HTML: 847

• MANAGEMENT OF HBV INFECTION DURING IMMUNOSUPPRESIVE TREATMENT

  Alfredo Marzano

  e2009025

  https://doi.org/10.4084/mjhid.2009.025

  928

  PDF: 522

  HTML: 1318

• THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition

  Emiliano Fabiani, Dr. Falconi, Dr. Cristiano, Dr. Hajrullaj, Dr. Falconi, Prof. Leone, Prof. Voso

  e2023064

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.064

  1586

  PDF: 1013

  HTML: 265

• VON WILLEBRAND FACTOR, ANGIODYSPLASIA AND ANGIOGENESIS

  Anna M. Randi, Mike A Laffan, Richard D. Starke

  e2013060

  2013-09-02

  https://doi.org/10.4084/mjhid.2013.060

  3953

  PDF: 1678

  HTML: 8257

  Randi Fig: 234

• VON WILLEBRAND FACTOR ABNORMALITIES STUDIED IN THE MOUSE MODEL: WHAT WE LEARNED ABOUT VWF FUNCTIONS

  Caterina Casari, Cecile V Denis

  e2013047

  2013-07-10

  https://doi.org/10.4084/mjhid.2013.047

  2296

  PDF: 1032

  HTML: 9690

• Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY GENE THERAPY FOR HEMOPHILIA

  Bhavya S Doshi, Valder R Arruda, Valder R Arruda

  e2020069

  2020-09-08

  https://doi.org/10.4084/mjhid.2020.069

  2313

  PDF: 2026

  HTML: 536

• CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma

  Ugo Testa, Francesco D'Alò, Elvira Pelosi, Germana Castelli, Giuseppe Leone

  e2024012

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.012

  2504

  PDF: 1966

  HTML: 188

• IMPORTANCE OF CLASSICAL MORPHOLOGY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME

  Rosangela Invernizzi, Federica Quaglia, Matteo Giovanni Della Porta

  e2015035

  2015-04-26

  https://doi.org/10.4084/mjhid.2015.035

  3625

  PDF: 2359

  HTML: 23625

  Untitled: 305

  Untitled: 287

  Untitled: 309

• CURING HEMOGLOBINOPATHIES: CHALLENGES AND ADVANCES OF CONVENTIONAL AND NEW GENE THERAPY APPROACHES.

  Irene Motta, Valentina Ghiaccio, Andrea Cosentino, Laura Breda

  e2019067

  2019-10-30

  https://doi.org/10.4084/mjhid.2019.067

  3181

  PDF: 1941

  HTML: 944

• Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio

  Dr. Enrica A. Martino, Dr. G. Mele, Dr. F. Morabito, Dr. M. Gentile, Dr. E. Vigna

  e2025006

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.006

  2333

  PDF: 1710

  HTML: 735

• NOVEL DRUGS IN FOLLICULAR LYMPHOMA

  Giuseppe Rossi, Antonella Anastasia

  e2016061

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.061

  5947

  PDF: 1611

  HTML: 1677

  Untitled: 284

• THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETHAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY

  Ercole Brusamolino, Manuel Gotti, Valeria Fiaccadori

  e2012022

  2012-04-06

  https://doi.org/10.4084/mjhid.2012.022

  2359

  PDF: 951

  HTML: 1994

• GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS

  Angela Stoddart, Megan E. McNerney, Elizabeth Bartom, Rachel Bergerson, David J. Young, Zhijian Qian, Jianghong Wang, Anthony A. Fernald, Elizabeth M. Davis, Richard A. Larson, Kevin P. White, Michelle M. Le Beau

  e2011019

  2011-05-16

  https://doi.org/10.4084/mjhid.2011.019

  2714

  PDF: 877

  HTML: 5393

• “IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”

  Sara Martinelli, Antonio Cuneo, Gian Matteo Rigolin

  e2016047

  2016-10-15

  https://doi.org/10.4084/mjhid.2016.047

  4119

  PDF: 1133

  HTML: 3912

  Untitled: 205

  Cneo. Fig.1: 147

  Untitled: 138

  Untitled: 172

  Untitled: 174

• APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Tadeusz Robak

  e2010011

  2010-05-07

  https://doi.org/10.4084/mjhid.2010.011

  1745

  PDF: 698

  HTML: 2452

• CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL

  Ugo Testa, Prof. Sica, Dr. Pelosi, Dr. Germana Castelli, Prof. Leone

  e2024010

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.010

  4731

  PDF: 3907

  HTML: 382

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2450

  PDF: 1905

  HTML: 1065

• PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma

  Ugo Testa; Giuseppe G.M. Leone

  e2025005

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.005

  2609

  HTML: 346

  PDF: 971

• FLUDARABINE-MELPHALAN-CAMPATH FOLLOWED BY UNMANIPULATED PERIPHERAL-BLOOD HAEMATOPOIETIC STEM CELLS CAN STILL CURE LYMPHOMA.

  Daniele Avenoso, Amal Alabdulwahab, Michelle Kenyon, Varun Mehra, Pramila Krishnamurthy, Francesco Dazzi, Ye Ting Leung, Sandra Anteh, Mili Naresh Shah, Andrea Kuhnl, Robin Sanderson, Piers Patten, Deborah Yallop, Antonio Pagliuca, Victoria Potter

  e2023041

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.041

  1738

  PDF: 798

  HTML: 252

• MANAGING INVASIVE FUNGAL INFECTIONS DURING ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION: A 2025 UPDATE

  Martina Quattrone, Alessia Di Pilla, Sara Brunetti, Antonio Giordano, Luana Fianchi, Livio Pagano, Marianna Criscuolo

  e2025064

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.064

  2694

  PDF: 1056

  HTML: 328

• TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi, Dr. Galli, Prof. Patrizia Chiusolo

  e2025039

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.039

  2667

  PDF: 1801

  HTML: 719

• The INFLUENCE OF NUTRITION ON DISEASE SEVERITY AND HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH SICKLE CELL DISEASE A Prospective Longitudinal Study

  Sanaa Kamal, Moheyeldeen Mohamed Naghib, Jamaan Al Zahrani, Huda Hassan, Karim Abdel Aziz Moawado, Omar Arrahman

  e2021007

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.007

  2652

  PDF: 1024

  HTML: 389

• ACUTE MYELOİD LEUKEMİA, MYELODYSPLASİA-RELATED: BEYOND CLASSİFİCATİON—TOWARD PRECİSİON DECİSİON-MAKİNG

  G Leone, U Testa, E Attardi, MT Voso

  e2026075

  2026-09-01

  https://doi.org/10.4084/MJHID.2026.075

  228

  PDF: 165

  Html: 147

• Successful treatment with eltrombopag in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia

  Alhossain A. Khalafallah, Zafreen Rahman, Kath Ogden, Terry Hannan

  e2012003

  2012-01-18

  https://doi.org/10.4084/mjhid.2012.003

  1601

  PDF: 918

  HTML: 1121

  Untitled: 224